Lamotrigine in the treatment of unipolar depression with and without comorbidities: A literature review

Psychiatric Quarterly

Volumn 83, Issue 3, 2012, Pages 371-383

  Zavodnick, Adam Daniel ^a,b   Ali, Rizwan ^c  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b Veterans Affairs Medical Cente   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; LITHIUM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

BORDERLINE STATE; DRUG USE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; REVIEW; SYSTEMATIC REVIEW;

ANTIMANIC AGENTS; ANXIETY DISORDERS; BORDERLINE PERSONALITY DISORDER; COMORBIDITY; DEPRESSIVE DISORDER; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZINES;

EID: 84866732948     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-012-9208-4     Document Type: Review

References (35)

1. Kemp DE, Muzina DJ, Gao K, Calabrese JR, Lamotrigine. In: Schatzberg AF, Nemeroff CB (Eds). The American Psychiatric Publishing textbook of psychopharmacology. Arlington, American Psychiatric, 2009
2. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. Journal of Clinical Psychopharmacology 23(5):484-495, 2003
3. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34(2):312-322, 1993
4. Calabrese JR, Bowden CL, Sachs G, et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64:1013-1024, 2003
5. Bowden CL, Calabrese JR, Sachs G, et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60:392-400, 2003
6. Goodwin GM, Bowden CL, Calabrese JR, et al.: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65:432-441, 2004
7. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 20(6):607-614, 2000
8. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM: Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biological Psychiatry 51(3):253-260, 2002
9. Normann C, Hummel B, Schärer LO, Hörn M, Grunze H, Walden J: Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. Journal of Clinical Psychiatry 63(4):337-344, 2002
10. Barbee JG, Jamhour NJ: Lamotrigine as an augmentation agent in treatment-resistant depression. Journal of Clinical Psychiatry 63(8):737-741, 2002
11. Rocha FL, Hara C: Lamotrigine augmentation in unipolar depression. International Clinical Psychopharmacology 18(2):97-99, 2003
12. Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 64(4):403-407, 2003
13. Gutierrez RL, McKercher RM, Galea J, Jamison KL. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr. IEEE Transactions on Pattern Analysis and Machine Intelligence 10(10):800-805, 2005.
14. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety 23(8):485-488, 2006
15. Schindler F, Anghelescu IG: Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology 22(3):179-182, 2007
16. Santos MA, Rocha FL, Hara C: Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Primary Care Companion to the Journal of Clinical Psychiatry 10(3):187-190, 2008
17. Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC: A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. Journal of Clinical Psychiatry 72(10):1405-1412, 2011
18. Mula M, Pini S, Cassano GB: The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. Journal of Clinical Psychopharmacology 27(3):263-272, 2007 (Review)
19. Masdrakis VG, Papadimitriou GN, Oulis P: Lamotrigine administration in panic disorder with agoraphobia. Clinical Neuropharmacology 33(3):126-128, 2010
20. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Australian and New Zealand Journal of Psychiatry 34(3):527-528, 2000
21. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, Davidson JR. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry 45(9):1226-1229, 1999
22. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, Nickel MK. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology (3):287-291, 2005
23. Leiberich P, Nickel MK, Tritt K, Pedrosa Gil F. Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. Journal of Psychopharmacology 22(7):805-808, 2008
24. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology 24(5):270-275, 2009
25. Maltese TM: Adjunctive lamotrigine treatment for major depression. American Journal of Psychiatry 156(11):1833, 1999
26. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 63(19):2029-2050, 2003 (Review)
27. Thase ME, Rush AJ: When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry 58(suppl 13):23-29, 1997
28. Fava M: Diagnosis and definition of treatment-resistant depression. Biological Psychiatry 53:649-659, 2003
29. *D report. American Journal of Psychiatry 163(11):1905-1917, 2006
30. Saggese JM, Lieberman DZ, Goodwin FK: The role of recurrence and cyclicity in differentiating mood disorder diagnoses. Primary Psychiatry 13(11):43-48, 2006
31. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U: Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biological Psychiatry 56:441-446, 2004
32. Wilder-Willis KE, Sax KW, Rosenberg HL, Fleck DE, Shear PK, Strakowski SM: Persistent attentional dysfunction in remitted bipolar disorder. Bipolar Disorders 3(2):58-62, 2001
33. Gualtieri CT, Johnson LG: Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. Med Gen Med 23; 8(3):46, 2006
34. Marciani MG, Stanzione P, Mattia D, Spanedda F, Bassetti MA, Maschio M, Bernardi G: Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clinical Neuropharmacology 21(1):41-47, 1998
35. Tiihonen J, Wahlbeck K, Kiviniemi V: The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 109 (1-3):10-14, 2009 (Review)